In a 50-year-old man on statin therapy with normal total cholesterol and markedly elevated triglycerides (~5.3 mmol/L) and no history of cardiovascular disease, diabetes, or hypertension, what is the most appropriate next step in management?

Omega-3 fatty acids (specifically icosapent ethyl) is the most appropriate next step

In this 50-year-old man already on statin therapy with normal cholesterol but elevated triglycerides at 5.3 mmol/L (~470 mg/dL), the most appropriate management is to add omega-3 fatty acids, specifically icosapent ethyl if he has additional cardiovascular risk factors.

Clinical Context and Risk Stratification

This patient has moderate hypertriglyceridemia (TG 150-499 mg/dL or 1.7-5.6 mmol/L). His triglyceride level of 5.3 mmol/L (~470 mg/dL) falls just below the severe threshold of 500 mg/dL where pancreatitis prevention becomes the primary concern 1, 2.

Since he's already on statin therapy with controlled LDL cholesterol, the key question is whether he qualifies for additional triglyceride-targeted therapy for residual cardiovascular risk reduction.

Evidence-Based Treatment Algorithm

Step 1: Optimize Existing Statin Therapy

• Ensure he's on maximally tolerated statin dose
• Verify LDL-C is at goal (ideally <100 mg/dL for primary prevention)
• His cholesterol is noted as "within normal range," suggesting adequate statin effect 1

Step 2: Assess Cardiovascular Risk Profile

The 2021 ACC Expert Consensus 1 established criteria based on the REDUCE-IT trial:

• Icosapent ethyl is indicated if patient has:
  • ASCVD (which he doesn't have) OR
  • Diabetes + ≥2 additional CV risk factors (need to assess)
  • TG ≥150 mg/dL on statin therapy (✓ he meets this)
  • LDL-C controlled on statin (✓ appears met)

Step 3: Treatment Selection

If he has diabetes or multiple CV risk factors:

• Answer: B - Omega-3 fatty acids (specifically icosapent ethyl 4g daily)
• REDUCE-IT demonstrated 25% relative risk reduction in major adverse cardiovascular events 1, 3
• This is the only triglyceride-lowering therapy with proven cardiovascular benefit 3, 4

If he lacks additional risk factors (primary prevention, low risk):

• Continue statin monotherapy
• Aggressive lifestyle modification
• Rule out secondary causes (alcohol, uncontrolled diabetes, hypothyroidism, medications)
• Consider omega-3 fatty acids for TG reduction, though CV benefit not proven in this lower-risk group

Why Not the Other Options?

A - Additional Statin (Incorrect)

• He's already on a statin with controlled cholesterol
• Statins have modest TG-lowering effect (10-30%) 2
• Statins should not be used as monotherapy for severe/very severe hypertriglyceridemia 2
• Adding more statin won't address residual triglyceride-mediated risk

C - Niacin (Incorrect)

• FDA withdrew approval for niacin in combination with statins in 2016 due to unfavorable benefit-risk profile 5
• No proven cardiovascular benefit in outcome trials 2
• Significant side effects (flushing, hepatotoxicity, glucose intolerance)

D - Fibrates (Incorrect)

• Fibrates are primarily indicated for severe hypertriglyceridemia (TG ≥500 mg/dL) to prevent pancreatitis 2, 6
• Post-hoc analyses show benefit only in patients with TG >200 mg/dL AND low HDL 2, 7
• No overall mortality benefit demonstrated in clinical trials 2
• His TG level (470 mg/dL) is borderline but not in the severe range where fibrates are first-line

Critical Dosing Information

Omega-3 fatty acids for hypertriglyceridemia:

• Prescription icosapent ethyl (purified EPA): 2g twice daily (4g total)
• Generic omega-3 preparations require 3-4g EPA+DHA daily for 20-50% TG reduction 2
• Over-the-counter fish oil has variable EPA/DHA content (20-50%) and requires multiple capsules 2

Common Pitfalls to Avoid

1. Don't confuse over-the-counter fish oil with prescription icosapent ethyl - only the latter has proven CV benefit 1, 3
2. Don't use fibrates as first-line unless TG >500 mg/dL or patient has contraindications to omega-3s 2, 6
3. Don't forget to assess for secondary causes of hypertriglyceridemia before adding therapy 1, 4
4. Don't assume all omega-3 products are equivalent - REDUCE-IT used purified EPA, not EPA+DHA combinations 1, 3

Additional Considerations

Before initiating omega-3 therapy, evaluate:

• Alcohol consumption (major TG elevator)
• Glycemic control if diabetic (HbA1c target <7%)
• Medications that raise TG (thiazides, beta-blockers, estrogens, steroids)
• Thyroid function
• Renal function
• Body weight and physical activity level 4, 5

The answer is B - Omega-3 fatty acids, with the caveat that prescription icosapent ethyl is preferred if the patient meets high-risk criteria per REDUCE-IT, while generic omega-3s can be used for TG lowering alone in lower-risk patients.